Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol

Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol

Introduction Janus kinase (JAK) inhibitors are an important therapeutic option in the treatment of rheumatoid arthritis, but increase the risk of developing herpes zoster. Although a dry recombinant zoster vaccine (RZV) that can be used under immunosuppressive conditions has recently been developed,...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuko Kaneko, Tsukasa Matsubara, Koichiro Ohmura, Toshihiro Matsui, Shigeto Tohma, Koichi Amano, Satoshi Takanashi, Shinji Sato, Atsushi Ihata, Kunihiro Yamaoka, Toshiaki Miyamoto, Jun Saegusa, Yasuko Mori, Kenta Misaki
Format: Article
Language:English
Published: BMJ Publishing Group 2024-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/11/e090668.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/14/11/e090668.full

Similar Items